You are here

Adipogenic and Metabolic Effects of Antipsychotic Drugs

Forms:    Download Registration Form in either: Microsoft Word   
Held On:    Mon 7/11/2011 - Tue 7/12/2011   
Location:    Hilton Newark Airport
1170 Spring Street
Elizabeth, NJ 07201
Conference Welcome Package   
Overview:   

Though possessing many advantages, many Antipsychotic drugs (APDs) have a major liability in their ability to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has witnessed substantial research effort aimed at quantifying, understanding, preventing, and alleviating these adverse effects and our goal is to provide a scientific update of these findings and discuss future research needs.

Organizing
Committee:
   
David Allison, Ph.D.

University of Alabama at Birmingham   
John Newcomer, M.D.
Miller School of Medicine, University of Miami    Christoph Correll, M.D.

Albert Einstein College of Medicine    Gary Remington MD PhD FRCPC

Centre for Addiction and Mental Health (CAMH), Canada    Elaine H. Morrato, DrPH MPH CPH

University of Colorado Denver   

Schedule of Events:

**NOTE: You will need Microsoft Silverlight to view videos.

DATE    TIME    SPEAKER/MODERATOR    TOPIC    VIDEO   
Day 1    8:00 - 8:05    David B. Allison, Ph.D., University of Alabama at Birmingham    Announcements/Business     
I. Magnitude and frequency of obesity, diabetes, and other metabolic disturbances among relevant patient populations.   
8:05 - 8:10    David B. Allison, PhD    Overview by Moderator     
8:10 - 8:40    John Newcomer, MD, Miller School of Medicine, University of Miami    Introduction and Scope of the Problem    video    
8:40 - 9:10    Marianne Ulcickas Yood, DSc, MPH, EpiSource, New York    Adoption of Metabolic Monitoring & Risk Management Practices    video    
9:10 - 9:40    Karen Teff, PhD, University of Pennsylvania    Atypical Antipsychotics: effects on post-prandial metabolism in healthy subjects, independent of weight gain or psychiatric disease    Video not available   
9:40 - 10:05    All speakers led by Moderator    Panel Discussion     
10:05 - 10:20    Break   
II. The magnitude of the adverse metabolic effects, how they differ by drug, and drugs on the horizon with more benign metabolic profiles.   
10:20 - 10:25    Julia M Gohlke, PhD, University of Alabama at Birmingham    Overview by Moderator     
10:25 - 10:55    Ginger Nicol MD, Washington University    Human studies of the effects of APDs on adiposity.    video    
10:55 - 11:25    David C. Henderson, MD, Harvard University    Human studies of the effects of APDs on glucose metabolism and other metabolic syndrome features.    video    
11:25 - 11:55    Christopher J Lynch, PhD Penn State University    Metabolomics and metabolic phenotyping after exposure to side effect prone atypical antipsychotics    video    
11:55 - 12:25    Christoph Correll, MD, Albert Einstein College of Medicine    Effects in children, adolescents, and first-break patients    video    
12:25 - 12:50    All speakers led by Moderator    Panel Discussion     
12:25 - 2:00    Lunch   
III. The biochemical, molecular, and mechanisms of these adverse APD effects.   
2:00 - 2:05    Dilip V. Jeste, MD, University of California, San Diego    Overview by Moderator     
2:05 - 2:35    Donard S. Dwyer, PhD, Louisiana State University    Findings in invertebrate models: Basic mechanisms, neurotransmitter regulation, and neuroprotection.    video    
2:35 - 3:05    Marilyn Ader, PhD, University of Southern California    Findings in mammalian models: Physiologic effects on endocrine regulation and dysregulation.    video    
3:05 - 3:15    Break   
3:15 - 3:45    Henry Nasrallah, MD, University of Cincinnati    The links between metabolic disorders and cognitive impairments    video    
3:45 - 4:25    Anil K. Malhotra, MD, Albert Einstein College of Medicine    Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.    video    
4:25 - 4:50    All speakers led by Moderator    Panel Discussion     
DATE    TIME    SPEAKER/MODERATOR    TOPIC    VIDEO   
Day 2    8:00 - 8:05    David B. Allison, Ph.D., University of Alabama at Birmingham    Announcements/Business     
IV. The behavioral and energetic mechanisms of these adverse APD effects   
8:05 - 8:10    Vicki L. Ellingrod Ringold, PharmD, University of Michigan    Overview by Moderator     
8:10 - 8:45    Gary Remington MD PhD FRCPC, Centre for Addiction and Mental Health (CAMH), Canada    Rodent Models: a Viable Option?    video    
8:45 - 9:20    Vicki L. Ellingrod Ringold, PharmD, University of Michigan    Antipsychotics, N-3 fatty acids, and pharmacogenetic factors    video    
9:20 - 9:55    Kimberly A. Brownley, PhD, University of North Carolina, Chapel Hill    Human intake studies.    video    
9:55 - 10:25    All speakers led by Moderator    Panel Discussion     
10:25 - 10:35    Break   
V. The safety and efficacy of treatment and prevention strategies to reduce these adverse effects   
10:35 - 10:40    Mary T. Weber, PhD, APRN, BC, PMHNP, University of Colorado Denver    Overview by Moderator     
10:40 - 11:10    Rohan Ganguli, MD, University of Pittsburgh at Pittsburgh    Lifestyle treatments to reduce adverse weight and metabolic effects    video    
11:10 - 11:40    Trino Baptista, MD, PhD, Los Andes University Medical School, Mérida, Venezuela    Pharmacologic treatments to reduce adverse weight & metabolic effects    video    
11:40 - 12:10    Tony Cohn, MB ChB FRCPC, Department of Psychiatry, University of Toronto    What are the metabolic benefits in switching antipsychotics and what are the risks?    video    
12:10 -12:35    All speakers led by Moderator    Panel Discussion     
12:35 - 1:45    Lunch   
VI. Methodological issues   
1:45 - 1:50    John Newcomer, M.D., Miller School of Medicine, University of Miami    Overview by Moderator     
1:50 - 2:20    David B. Allison, PhD, University of Alabama at Birmingham    Methodological issues in designing, analyzing, and interpreting randomized clinical trials of APD metabolic effects    video    
2:20 - 2:50    Elaine H. Morrato,DrPH, University of Colorado Denver    Methodologic issues in epidemiologic and pharmacovigilance studies of APD metabolic effects.    video    
2:50 - 3:05    Break   
VII. Translational Science & Personalized Medicine   
3:05 - 3:10    Lydia Chwastiak, MD, PhD, Yale University    Overview by Moderator     
3:10 - 3:40    Stephen Crystal, PhD, Rutgers University    Broadened Use of Atypical Antipsychotics: Trends and Challenges for Policymakers, Clinicians, and Patients    video    
3:40 - 4:10    Deanna Kelly, PharmD, University of Maryland    Metabolic and behavioral predictors of response and their implications for choice of treatment.    video    
4:10 - 4:35    All speakers led by Moderator    Panel Discussion     

UAB Speakers:

External Speakers:

Contact Information:

Logistics: Jeff Allison
University of Alabama at Birmingham
1530 3rd Avenue South
Webb 402 3361
Birmingham, AL 35294-3361
Phone: (205) 975-9675
Email: norc@uab.edu      Scientific: David B. Allison, Ph.D.
University of Alabama at Birmingham
1665 University Blvd, RPHB 420C
Birmingham, AL 35294-0022
Phone: (205) 975-9169
Email: dallison@uab.edu   

Funded by:

Funding for this conference was made possible (in part) by (R13MH086166) from the National Institute of Mental Health ( NIMH) and the National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S Government.   

Sponsors:

Nutrition Obesity Research Center,
University of Alabama at Birmingham     

Contributors:

Women, members of underrepresented minority groups and individuals with disabilities are strongly encouraged to apply.

Assistive Options

Top of page


Assistive Options

Open the original version of this page.

Usablenet Assistive is a Usablenet product. Usablenet Assistive Main Page.